

Linda F Stein Gold

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3716208/publications.pdf>

Version: 2024-02-01

71
papers

1,852
citations

361388

20
h-index

289230

40
g-index

71
all docs

71
docs citations

71
times ranked

1243
citing authors

#	ARTICLE	IF	CITATIONS
1	Vehicles for atopic dermatitis therapies: more than just a placebo. <i>Journal of Dermatological Treatment</i> , 2022, 33, 685-698.	2.2	21
2	Efficacy, safety, usability, and acceptability of risankizumab 150mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2085-2093.	2.2	7
3	Posttreatment maintenance of therapeutic effect with fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion for moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2068-2074.	2.2	1
4	Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 77-85.	1.2	21
5	Janus kinase inhibitors in dermatology: Part I. A comprehensive review. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 406-413.	1.2	26
6	Janus kinase inhibitors in dermatology: Part II. A comprehensive review. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 414-422.	1.2	31
7	Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 93-104.	6.7	11
8	A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 228-236.	2.4	21
9	Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 69-81.	6.7	24
10	Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis. <i>JAMA Dermatology</i> , 2022, 158, 404.	4.1	90
11	Sarecycline treatment for acne vulgaris: Rationale for weight-based dosing and limited impact of food intake on clinical efficacy. <i>Dermatologic Therapy</i> , 2022, 35, e15275.	1.7	9
12	Short Term and Long-Term Efficacy of Calcipotriene/ Betamethasone Dipropionate Foam Combination. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2022, Volume 15, 809-814.	1.8	1
13	Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 735.	4.1	22
14	Isotretinoin Laboratory Monitoring in Acne Treatment. <i>JAMA Dermatology</i> , 2022, 158, 942.	4.1	12
15	Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor modulating agent. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1059-1067.	1.2	92
16	Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1269-1277.	1.2	38
17	Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology. <i>Journal of Dermatological Treatment</i> , 2021, 32, 391-398.	2.2	20
18	Efficacy and safety of fixed-dose combination calcipotriol/betamethasone dipropionate foam for the treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 10-19.	2.4	8

#	ARTICLE	IF	CITATIONS
19	Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1152-1160.	2.4	12
20	A Phase 3, Randomized Trial Demonstrating the Improved Efficacy and Patient Acceptability of Fixed Dose Calcipotriene and Betamethasone Dipropionate Cream. <i>Journal of Drugs in Dermatology</i> , 2021, 20, 420-425.	0.8	14
21	A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 624-631.	1.2	31
22	50 Years of Topical Retinoids for Acne: Evolution of Treatment. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 315-327.	6.7	29
23	Why We Should Consider Evidence-Based Treatment Options for Truncal Acne. <i>Dermatology and Therapy</i> , 2021, 11, 661-664.	3.0	1
24	Clinical, patient and estimated cost benefits of proactive management versus reactive management with calcipotriol/betamethasone dipropionate foam for the treatment of plaque psoriasis in Finland. <i>Journal of Dermatological Treatment</i> , 2021, , 1-19.	2.2	3
25	Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits. <i>Dermatology and Therapy</i> , 2021, 11, 1157-1174.	3.0	4
26	Acne Scarring: Why We Should Act Sooner Rather Than Later. <i>Dermatology and Therapy</i> , 2021, 11, 1075-1078.	3.0	3
27	New topical therapies for psoriasis. <i>Dermatological Reviews</i> , 2021, 2, 262-268.	0.5	4
28	Tapinarof cream 1% once daily and benvitimod 1% twice daily are 2 distinct topical medications. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, e201-e202.	1.2	10
29	25750 Tapinarof cream 1% once daily for plaque psoriasis: Secondary efficacy outcomes from two pivotal phase 3 trials. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, AB69.	1.2	2
30	Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021, 385, 2219-2229.	27.0	93
31	PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis. <i>Advances in Therapy</i> , 2020, 37, 4730-4753.	2.9	6
32	Topical Therapies for Psoriasis in Phase 3 Trials. <i>Current Dermatology Reports</i> , 2020, 9, 331-338.	2.1	0
33	PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 131-138.	1.2	9
34	Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1501-1510.	1.2	89
35	Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Lotion for the Treatment of Plaque Psoriasis in Patients With 3-5% Body Surface Area. <i>SKIN the Journal of Cutaneous Medicine</i> , 2020, 4, s78.	0.3	1
36	Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion. <i>SKIN the Journal of Cutaneous Medicine</i> , 2020, 4, s79.	0.3	1

#	ARTICLE	IF	CITATIONS
37	Halobetasol 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females. <i>Journal of Drugs in Dermatology</i> , 2020, 19, 504-514.	0.8	1
38	Halobetasol 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females. <i>Journal of Drugs in Dermatology</i> , 2020, 19, 504-514.	0.8	1
39	Itch: an underrecognized problem in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1465-1476.	2.4	63
40	Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 282-285.	1.2	19
41	Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis. <i>Journal of Drugs in Dermatology</i> , 2019, 18, 279-284..	0.8	5
42	Understanding topical therapies for psoriasis. <i>Cutis</i> , 2019, 103, S8-S12.	0.3	2
43	Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Foam Formulation of Halobetasol Propionate, 0.05% vs Its Vehicle in Adult Subjects With Plaque Psoriasis. <i>Journal of Drugs in Dermatology</i> , 2019, 18, 790-796.	0.8	2
44	Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 287-293.	1.2	48
45	Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies. <i>Journal of Drugs in Dermatology</i> , 2018, 17, 855-861.	0.8	8
46	Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy. <i>Journal of Drugs in Dermatology</i> , 2018, 17, 1280-1287.	0.8	10
47	Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 405-411.	6.7	24
48	A dose-finding trial with a novel ingenol derivative (ingenol disoxate: LEO 43204) for field treatment of actinic keratosis on full face or 250â€cm ² on the chest. <i>Journal of Dermatological Treatment</i> , 2017, 28, 652-658.	2.2	10
49	Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 119-126.	2.4	92
50	Atopic Dermatitis Progression: Evaluating Intervention Strategies. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2017, 36, S39-S41.	1.6	1
51	Nonpharmacologic Strategies and Topical Agents for Treating Atopic Dermatitis: An Update. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2017, 36, S42-S44.	1.6	1
52	A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis. <i>Journal of Drugs in Dermatology</i> , 2017, 16, 197-204.	0.8	19
53	Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled Studies. <i>Skinmed</i> , 2017, 15, 119-124.	0.0	22
54	Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study. <i>Journal of Drugs in Dermatology</i> , 2017, 16, 801-808.	0.8	38

#	ARTICLE	IF	CITATIONS
55	Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam is Effective, Independent of Body Mass Index and the Extent and Severity of Psoriasis. <i>Dermatology and Therapy</i> , 2016, 6, 667-673.	3.0	5
56	Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 494-503.e6.	1.2	425
57	Moderate and Severe Inflammatory Acne Vulgaris Effectively Treated with Single-Agent Therapy by a New Fixed-Dose Combination Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel: A Randomized, Double-Blind, Parallel-Group, Controlled Study. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 293-303.	6.7	40
58	Adapalene-benzoyl Peroxide Gel is Efficacious and Safe in Adult Female Acne, with a Profile Comparable to that Seen in Teen-aged Females. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016, 9, 23-29.	0.1	4
59	Improvement in Extensive Moderate Plaque Psoriasis With a Novel Emollient Spray Formulation of Betamethasone Dipropionate 0.05. <i>Journal of Drugs in Dermatology</i> , 2016, 15, 334-42.	0.8	11
60	Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled Studies. <i>Journal of Drugs in Dermatology</i> , 2016, 15, 951-7.	0.8	26
61	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2015, 8, S4-S26.	0.1	1
62	Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris—a Randomized Phase III Study (PSO-FAST). <i>Journal of Drugs in Dermatology</i> , 2015, 14, 1468-77.	0.8	63
63	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm Meeting. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2014, 7, S5-S22.	0.1	0
64	Efficacy and tolerability of fixed-combination acne treatment in adolescents. <i>Cutis</i> , 2013, 91, 152-9.	0.3	6
65	What's new in acne and inflammation?. <i>Journal of Drugs in Dermatology</i> , 2013, 12, s67-9.	0.8	2
66	Synergistic efficacy of adapalene 0.1%-benzoyl peroxide 2.5% in the treatment of 3855 acne vulgaris patients. <i>Journal of Dermatological Treatment</i> , 2011, 22, 197-205.	2.2	38
67	Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, double-blind study of adapalene 0.1%-benzoyl peroxide 2.5% fixed-dose combination gel with doxycycline hyclate 100 mg. <i>Cutis</i> , 2010, 85, 94-104.	0.3	38
68	Fixed-combination products in the management of acne vulgaris. <i>Cutis</i> , 2010, 85, 160-7.	0.3	3
69	Calcitriol ointment: optimizing psoriasis therapy. <i>Journal of Drugs in Dermatology</i> , 2009, 8, s23-7.	0.8	7
70	A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. <i>Cutis</i> , 2009, 84, 110-6.	0.3	50
71	The MORE trial: effectiveness of adapalene gel 0.1% in real-world dermatology practices. <i>Cutis</i> , 2006, 78, 12-8.	0.3	0